BofA raised the firm’s price target on Incyte (INCY) to $104 from $90 and keeps a Buy rating on the shares after meeting with its CEO. Bill Meury highlighted his confidence in Incyte’s long-term growth potential driven by the existing commercial portfolio and maturing pipeline focusing on heme/onc and immunology and backed by a strong balance sheet, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY: